Achieve Life Sciences
Develops cytisinicline for nicotine dependence across smoking-cessation and vaping-cessation programs.
Something off on this page? Send us feedback.
Profile
Develops cytisinicline, an investigational treatment for nicotine dependence. Its single operating segment covers development and potential commercialization, with operations in Canada, the United States, and the United Kingdom.
Develops cytisinicline, an investigational treatment for nicotine dependence. Its single operating segment covers development and potential commercialization, with operations in Canada, the United States, and the United Kingdom.
The lead smoking-cessation application received an FDA Complete Response Letter tied to observations at a prior third-party manufacturing facility and unfinished labeling. The company has said it intends to resubmit using Adare Pharma Solutions as primary manufacturer.
A separate vaping-cessation track has completed a Phase 2 study and an end-of-Phase-2 FDA meeting. The business remains dependent on FDA approval of cytisinicline, its only reportable product family.
Company facts
Key statistics
Year to date +63.2% · Average volume (30d) 1.2M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 13, 2026 | Morgan Stanley | Initiate | Overweight | $13 | |
| Aug 12, 2026 | Raymond James | Reiterate | Strong Buy | $20 | $18 |
| Aug 12, 2026 | H.C. Wainwright | Reiterate | Buy | $12 | |
| Jun 26, 2026 | Raymond James | Target | $20 | ||
| Apr 20, 2026 | Canaccord Genuity | Target | $13 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 11, 2026Q2 FY26 | −$0.16 | −$0.80 | −385.2% | — | — | — | +1.50% |
| May 12, 2026Q1 FY26 | −$0.30 | −$0.19 | +36.7% | — | — | — | −0.50% |
| Mar 24, 2026Q4 FY25 | −$0.27 | −$0.28 | −3.7% | — | — | — | −2.76% |
| Nov 6, 2025Q3 FY25 | −$0.24 | −$0.28 | −16.7% | — | — | — | −3.16% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | −$54.0K | $0 | −$57.0K | $0 | |
| Operating income | −$12.9M | −$12.6M | −$14.7M | −$14.7M | −$10.5M | −$18.4M | |
| Net income | −$12.8M | −$12.7M | −$14.4M | −$14.7M | −$10.2M | −$74.8M | |
| Diluted EPS | −$0.37 | −$0.37 | −$0.28 | −$0.28 | −$0.19 | −$0.80 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $187.3M · Total debt $14.9M · Total assets $190.4M · Shareholders' equity −$14.7M
Dividends
No dividends on record.
Ownership
Shares outstanding 102.66M · Float 87.47M · 85.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| venBio Global Strategic GP V, LLC | 10.74M | 9.99% | 13D | Apr 27, 2026 |
| Logos Global Management LP | 10.54M | 9.99% | 13G | Aug 17, 2026 |
| Paradigm BioCapital Advisors LP | 9.90M | 9.20% | 13G | Apr 24, 2026 |
| TPG GP A, LLC · 10 percent owner | 6.88M | 6.70% | Form 4 | Apr 24, 2026 |
| Frazier Life Sciences Public Fund, L.P. | 6.63M | 6.50% | 13G | Apr 24, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 19, 2026 | Richard Alistair Stewart | director | −20,626 | $8.49 |
| Sep 18, 2025 | Richard Alistair Stewart | director, officer: Chief Executive Officer | −129,501 | $2.92 |
| Sep 18, 2025 | Mark K. Oki | officer: Chief Financial Officer | −50,060 | $2.92 |
| Sep 4, 2025 | Jaime Xinos | officer: Chief Commercial Officer | −20,854 | $2.77 |
| Sep 4, 2025 | Cindy Jacobs | officer: President & CMO | −27,629 | $2.77 |
Peers
- Dr. Reddy's Laboratories (ADR)
Global nicotine-replacement therapies for smoking and vaping cessation
- Teva (ADR)
Generic bupropion and varenicline options for smoking cessation
- Pfizer
Varenicline therapy for adult smoking cessation
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Achieve Life Sciences | $8.26 | +1.85% | $831.5M | — | — | — | — |
| Dr. Reddy's Laboratories (ADR) | $12.18 | 0.00% | $10.15B | 29.2 | 32.5 | 3.0 | −16.2% |
| Teva (ADR) | $36.30 | −0.36% | $42.44B | 60.7 | 12.9 | 2.5 | −0.8% |
| Pfizer | $27.95 | −0.04% | $159.36B | 36.9 | 10.0 | 2.5 | +2.6% |
| Median | 36.9 | 12.9 | 2.5 | −0.8% |